Clinical Trial

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-03-19; most recent amendment 2026-03-13.
Status change: Active, Not Recruiting → Completed 2025-12-09
Status change: Recruiting → Active, Not Recruiting 2025-09-30
Status change: Not Yet Recruiting → Recruiting 2025-04-17
Trial Details
NCT Number NCT06894771
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Malignant Neoplasm
Enrollment 5 participants
Start Date 2025-04-23
Primary Completion 2025-12-08 (estimated)
Study Completion 2025-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-16